Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.
暂无分享,去创建一个
Jakob Nikolas Kather | C. Tournigand | N. Loménie | M. Maiuri | J. Pawlotsky | J. Calderaro | Narmin Ghaffari Laleh | S. Caruso | P. Maillé | D. Sommacale | D. Gentien | A. Rapinat | G. Amaddeo | A. Laurent | Qinghe Zeng | C. Charpy | H. Regnault | R. Brustia | C. Nguyễn | C. Klein | Audrey Rapinat
[1] Chiun Hsu,et al. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives , 2021, Seminars in Liver Disease.
[2] J. Llovet,et al. Evidence-based management of HCC: Systematic review and meta-analysis of randomized controlled trials (2002-2020). , 2021, Gastroenterology.
[3] V. Mazzaferro,et al. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. , 2021, Gastroenterology.
[4] Jakob Nikolas Kather,et al. Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers , 2020, Gut.
[5] J. Furuse,et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma , 2020, Journal of hepatology.
[6] Yumin Li,et al. The advances in immunotherapy for hepatocellular carcinoma , 2020 .
[7] Jakob Nikolas Kather,et al. Development of AI-based pathology biomarkers in gastrointestinal and liver cancer , 2020, Nature Reviews Gastroenterology & Hepatology.
[8] Ming Y. Lu,et al. AI-based pathology predicts origins for cancers of unknown primary , 2020, Nature.
[9] Alexander T. Pearson,et al. Clinical-grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. , 2020, Gastroenterology.
[10] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[11] P. Chow,et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. , 2020, Future oncology.
[12] Ming Y. Lu,et al. Data-efficient and weakly supervised computational pathology on whole-slide images , 2020, Nature Biomedical Engineering.
[13] Oumeima Laifa,et al. Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides , 2020, Hepatology.
[14] J. Xia,et al. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma , 2020, Cancer Immunology, Immunotherapy.
[15] M. Ziol,et al. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma , 2020, Hepatology.
[16] M. Ziol,et al. Molecular and histological correlations in liver cancer. , 2019, Journal of hepatology.
[17] T. Chan,et al. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy , 2019, Nature Reviews Cancer.
[18] M. Kudo,et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[19] N. Razavian,et al. Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning , 2018, Nature Medicine.
[20] J. Llovet,et al. Molecular therapies and precision medicine for hepatocellular carcinoma , 2018, Nature Reviews Clinical Oncology.
[21] Gisela Schwab,et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.
[22] A. Luciani,et al. Macrotrabecular‐massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance , 2018, Hepatology.
[23] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[24] S. Imbeaud,et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.
[25] J. Lunceford,et al. IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.
[26] Steven J. M. Jones,et al. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.
[27] Peter Bankhead,et al. QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.
[28] Masatoshi Kudo,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[29] A. Luciani,et al. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features , 2016, Hepatology.
[30] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[31] Elena Deza,et al. Encyclopedia of Distances , 2014 .
[32] P. Legendre,et al. Ward's Hierarchical Clustering Method: Clustering Criterion and Agglomerative Algorithm , 2011, ArXiv.
[33] Rodney X. Sturdivant,et al. Applied Logistic Regression: Hosmer/Applied Logistic Regression , 2005 .
[34] J. Zucman‐Rossi,et al. Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.